Recognize Announces Strategic Investment in SDG Corporation
Partnership will focus on further buildout of leading cybersecurity solutions provider NEW YORK, Dec. 9, 2024 /PRNewswire/ — Recognize, a private equity firm focused on investing in digital services businesses, today announced that it has made a significant strategic investment in SDG Corporat
Miami-Dade County Commission Vice Chairman Kionne L. McGhee Honors Dr. Desmond Meade with Street Naming Ceremony
MIAMI, Dec. 9, 2024 /PRNewswire/ — In a powerful and emotional ceremony on Friday, December 6, Miami-Dade County Commission Vice Chairman Kionne L. McGhee honored Dr. Desmond Meade, a visionary advocate for justice and equality, by renaming a portion of Southwest 268th Street (Moody Drive) as
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
WESTON, Fla., Dec. 9, 2024 /PRNewswire/ — Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orph
" title="State Grid Kizilsu Kirghiz Autonomous Prefecture Electric Power Supply Company has demonstrated its capability in achieving a “zero perception” of customers’ electricity consumption through live working practices
ARTUSH, China, Dec. 9, 2024 /PRNewswire/ — Recently, the company successfully completed a live working task on the 10kV “Tan An Line” 1011. Throughout this operation, the customer’s equipment maintained normal operational status, effectively realizing a “zero perception
Hair Growth Drug Safe at Low Doses for Breast Cancer Patients
NEW YORK, Dec. 9, 2024 /PRNewswire/ — Hair loss during chemotherapy can cause enough distress for some women to lose self-confidence, which experts say may discourage them from seeking chemotherapy in the first place. Oral minoxidil is a commonly prescribed treatment for hair loss. The drug is
State Grid Kizilsu Kirghiz Autonomous Prefecture Electric Power Supply Company actively provides services to ensure the safe and stable electricity consumption of heating enterprises.
ARTUSH, China, Dec. 9, 2024 /PRNewswire/ — Recently, the State Grid Kizilsu Kirghiz Autonomous Prefecture Electric Power Supply Company actively responded to the demand for winter heating, went deep into Meijia Thermal Power Co., Ltd. in Aheqi County to conduct a safe electricity inspection t
The U.S. Department of Homeland Security, Israel’s National Cyber Directorate, and the BIRD Foundation, Announce a Cybersecurity Call for Proposals
Approved projects will be awarded funding up to $1.5M TEL AVIV, Israel and WASHINGTON, Dec. 9, 2024 /PRNewswire/ — The U.S. Department of Homeland Security (DHS) Science and Technology Directorate (S&T), the Israel National Cyber Directorate (INCD), and the Israel-U.S. Binational Industr
Ballard to Supply 8 MW of Fuel Cell Engines to Stadler for Californian Passenger Rail
VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ – Ballard Power Systems (NASDAQ: BLDP) (TSX: BLDP) today announced the signing of a multi-year supply agreement with Stadler US (“Stadler”; www.stadlerrail.com) to supply 8 megawatts of FCmove®-HD+ fuel cell engines to power trains for the
Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate
BEIJING, Dec. 9, 2024 /PRNewswire/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that the National Medica
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
Publication follows oral presentation at the American Society of Hematology (ASH) Annual Meeting Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95% Additional IIT data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma shows
